Patrick Daly

Cancer Nursing Today nonprod

Recent first-line randomized controlled trials (RCTs) for patients with diffuse large B-cell lymphoma (DLCBL) have demonstrated negative results which, according to Robert Andrew Harkins and colleagues, &ldquo;may be due in part to onerous eligibility criteria limiting enrollment of poor-risk patients who require immediate treatment.&rdquo; Therefore, Harkins and collaborators surveyed lymphoma experts in the United States to define essential and non-essential enrollment criteria in an effort to improve the clinical diversity in cohorts of modern RCTs evaluating first-line DLBCL treatments.The investigators initially collated the enrollment criteria of 19 RCTs conducted during the rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) &ldquo;era&rdquo; to identify common eligibility criteria for inclusion in a Delphi-method survey. A total of 451 eligibility criteria covering 51 criterion categories were tabulated from the R-CHOP RCTs. The study&rsquo;s contributors then surveyed lymphoma clinical trial experts from eight academic medical centers on essential and unnecessary eligibility criteria.A total of 29 clinical investigators were invited to respond to the first round of the survey. Seventeen experts completed the round one questionnaire (response rate = 58.6%), and 15 of those completed the round two survey (88.2%). Lastly, all round one participants reviewed the finalized recommendations for eligibility criteria.Ultimately, the authors reported that they defined consensus recommendations for 31 improved eligibility criteria, &ldquo;including threshold values for 10 quantitative eligibility criteria aimed at facilitating enrollment of a clinical diverse study population in first-line DLBCL RCTs designed to improve standard of care therapy.&rdquo; Validation of these updated enrollment criteria guidelines is warranted after future RCTs on first-line DLBCL treatments are conducted.

Improving Enrollment Criteria for Trials of First-Line Treatment of DLBCL

Lymphoma

Recent first-line randomized controlled trials (RCTs) for patients with diffuse large B-cell lymphoma (DLCBL) have demonstrated negative results which, according to Robert Andrew Harkins and colleagues, “may be due in part to onerous eligibility criteria limiting enrollment of poor-risk patients who require immediate treatment.” Therefore, Harkins and collaborators surveyed lymphoma experts in the United States [...]

About Us

Editorial Policy

Authors

Advertising

eNewsletters

Contact Us

Contribute

Calendar of Events

Career Center

Blood Cancers Today

GU Oncology Now

DocWire News

MashupMD

Urban Health Today

Breast Cancer

Colorectal Cancer

GI Cancer

GU Cancer

Gynecologic Cancer Awareness Month

Gyn-Onc

Blood Cancer Awareness Month

GVHD

Leukemia

Myeloproliferative Neoplasms

Multiple Myeloma

Myelodysplastic Syndrome

Myelofibrosis

Sickle Cell

Hem/Onc

Professional Development

Patient Voice

Lung Cancer

Skin Cancer

Other Tumor Types

News

Treatment

More

Conferences

Calendar

CARE Award

Best Practices

Expert Interviews

Subscribe